For The Better

When a market is already $200 billion in size and could approach $300 billion, investors can’t afford to overlook it.

The jeans specialist reports fiscal 2021 third-quarter earnings in a few days.

Marqeta has formed partnerships with companies like Google, Square, and Goldman Sachs, but it’s still flying under many people’s radar.

The Pentagon will soon award contracts for a dozen-dozen new satellites.

Three oral antiviral therapies for COVID-19 are far along in development.

Here’s how Amplitude stacks up against Adobe and Google.

Gaming platform Skillz is spending aggressively on marketing; Aarki can make that task more effective.

The alcoholic beverage giant announces fiscal 2022 second-quarter earnings results in just a few days.

Its recent performance has been underwhelming, but its future still looks solid.

Here’s how OptimizeRx gets in front of physicians.

The uranium miner has notable plans and is starting to show some progress toward its big goals. Here’s what you need to know.

Could this technology be the future of the pharmaceutical industry?

The spice giant reduced profit targets while lifting its sales outlook.

Ford said last month that it has increased its production plans for the electric truck — but should it do even more?

Square is already a winner, but its ongoing mission to challenge the massive banking industry could mean there is even more upside ahead.

You’ll probably get a lot less than that.

This trio is down, but the market is underestimating the long-term potential of these stocks.

This healthcare deal was finalized a year ago. Was it the right move?

It’s an early mover, but the telehealth playing field is getting crowded.

Dividends combined with long-term growth and cheap valuations make these tech stocks buys right now.